Literature DB >> 10096969

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.

T A D'Amico1, M Massey, J E Herndon, M B Moore, D H Harpole.   

Abstract

OBJECTIVE: The standard treatment of patients with stage I non-small cell lung cancer is resection of the primary tumor; however, the recurrence rate is 28% to 45%. This study evaluates a panel of molecular markers in a large population of patients with stage I non-small cell lung cancer to determine the prognostic value of each marker and to create a biologic risk model.
METHODS: Pathologic specimens were collected from 408 consecutive patients after complete resection for stage I non-small cell lung cancer at a single institution, with follow-up of at least 5 years. A panel of 10 molecular markers was chosen for immunohistochemical analysis of the primary tumor on the basis of differing oncogenic mechanisms. Local tumor expansion requires growth regulating proteins (epidermal growth factor receptor, the protooncogene erb-b2); apoptosis proteins (p53, bcl-2); and cell cycle regulating proteins (retinoblastoma recessive oncogene, KI-67). Local tumor invasion requires angiogenesis (factor viii). The development of distant metastases involves the expression of adhesion proteins (CD-44, sialyl-Tn, blood group A). Cox proportional hazards regression analysis was used to construct an independent risk model for cancer recurrence and death.
RESULTS: Multivariable analysis demonstrated significantly elevated risk for the following molecular markers: p53 (hazard ratio, 1.68; P =.004); factor viii (hazard ratio, 1.47 P =. 033); erb-b2 (hazard ratio, 1.43; P =.044); CD-44 (hazard ratio, 1. 40; P =.050); and retinoblastoma recessive oncogene (hazard ratio, 0. 747; P =.084).
CONCLUSIONS: Five molecular markers were associated with the risk of recurrence and death, representing independent metastatic pathways: apoptosis (p53), angiogenesis (factor viii), growth regulation (erb-b2), adhesion (CD-44), and cell cycle regulation (retinoblastoma recessive oncogene). This study demonstrates the validity of this molecular biologic risk model in patients with stage I non- small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096969     DOI: 10.1016/s0022-5223(99)70294-1

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  37 in total

Review 1.  Molecular pathology of tumor metastasis. I. Predictive pathology.

Authors:  J Tímár; O Csuka; Z Orosz; A Jeney; L Kopper
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.

Authors:  H Nakamura; N Kawasaki; M Taguchi; K Kabasawa
Journal:  Thorax       Date:  2005-11-11       Impact factor: 9.139

3.  Exosomal miRNAs as biomarkers of recurrent lung cancer.

Authors:  Radha Munagala; Farrukh Aqil; Ramesh C Gupta
Journal:  Tumour Biol       Date:  2016-02-11

4.  Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients.

Authors:  Giuseppe Pelosi; Elisabetta Schianchi; Patrizia Dell'orto; Giulia Veronesi; Lorenzo Spaggiari; Felice Pasini; Gabriella Sozzi; Elisabeth Brambilla; Claudia Griso; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-09-29       Impact factor: 4.064

Review 5.  A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.

Authors:  Adam Yagui-Beltrán; David M Jablons
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-08       Impact factor: 1.520

6.  Lentivirus-mediated knockdown of CTDP1 inhibits lung cancer cell growth in vitro.

Authors:  Runbo Zhong; Xiaoxiao Ge; Tianqing Chu; Jiajun Teng; Bo Yan; Jun Pei; Liyan Jiang; Hua Zhong; Baohui Han
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-21       Impact factor: 4.553

7.  Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation.

Authors:  I Abdel Salam; H E Gaballa; N Abdel Wahab
Journal:  Med Oncol       Date:  2008-12-18       Impact factor: 3.064

8.  Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.

Authors:  Marianna Grinberg; Dijana Djureinovic; Hans Rr Brunnström; Johanna Sm Mattsson; Karolina Edlund; Jan G Hengstler; Linnea La Fleur; Simon Ekman; Hirsh Koyi; Eva Branden; Elisabeth Ståhle; Karin Jirström; Derek K Tracy; Fredrik Pontén; Johan Botling; Jörg Rahnenführer; Patrick Micke
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

Review 9.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

10.  Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis.

Authors:  Sukki Cho; Sook-Whan Sung; Sanghoon Jheon; Jin-Haeng Chung
Journal:  Lung       Date:  2008-10-04       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.